Serum inflammatory markers and risk of colorectal cancer in patients with inflammatory bowel diseases

Clinical Gastroenterology and Hepatology

Volumn 12, Issue 8, 2014, Pages

  Ananthakrishnan, Ashwin N ^a,b   Cheng, Su Chun ^c   Cai, Tianxi ^c   Cagan, Andrew ^d   Gainer, Vivian S ^d   Szolovits, Peter ^e   Shaw, Stanley Y ^a,b   Churchill, Susanne ^f   Karlson, Elizabeth W ^b,f   Murphy, Shawn N ^a,b,d   Kohane, Isaac ^b,f,g   Liao, Katherine P ^b,f  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d PARTNERS HEALTHCARE   (United States)

^e MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

C reactive protein; Colorectal cancer; Crohn's disease; ESR; Ulcerative colitis

Indexed keywords

C REACTIVE PROTEIN; MARKER; BIOLOGICAL MARKER; ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE;

ADULT; ARTICLE; BLOOD LEVEL; CANCER RISK; COLORECTAL CANCER; CONFOUNDING VARIABLE; DISEASE SEVERITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HUMAN; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; BLOOD; COHORT ANALYSIS; COLORECTAL NEOPLASMS; COMPLICATION; MIDDLE AGED; PATHOLOGY; RISK ASSESSMENT; CANCER DIAGNOSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; HEALTH CARE SYSTEM; MULTICENTER STUDY; PRIMARY MEDICAL CARE;

ADULT; BIOLOGICAL MARKERS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; COHORT STUDIES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; RISK ASSESSMENT;

EID: 84904386094     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.12.030     Document Type: Article

References (43)

1. Baumgart D.C., Sandborn W.J. Crohn's disease. Lancet 2013, 380:1590-1605.
2. Ordas I., Eckmann L., Talamini M., et al. Ulcerative colitis. Lancet 2013, 380:1606-1619.
3. Andersen V., Halfvarson J., Vogel U. Colorectal cancer in patients with inflammatory bowel disease: can we predict risk?. World JGastroenterol 2012, 18:4091-4094.
4. Eaden J. Review article: colorectal carcinoma and inflammatory bowel disease. Aliment Pharmacol Ther 2004, 20(Suppl 4):24-30.
5. Eaden J.A., Abrams K.R., Mayberry J.F. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001, 48:526-535.
6. Farraye F.A., Odze R.D., Eaden J., et al. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 2010, 138:738-745.
7. Ullman T., Odze R., Farraye F.A. Diagnosis and management of dysplasia in patients with ulcerative colitis and Crohn's disease of the colon. Inflamm Bowel Dis 2009, 15:630-638.
8. Jess T., Simonsen J., Jorgensen K.T., et al. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology 2012, 143:375-381. quiz e13-e14.
9. Loftus E.V. Epidemiology and risk factors for colorectal dysplasia and cancer in ulcerative colitis. Gastroenterol Clin North Am 2006, 35:517-531.
10. Sebastian S., Hernandez V., Myrelid P., et al. Colorectal cancer in inflammatory bowel disease: results of the 3rd ECCO pathogenesis scientific workshop (I). JCrohns Colitis 2014, 8:5-18.
11. Cairns S.R., Scholefield J.H., Steele R.J., et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 2010, 59:666-689.
12. Gupta R.B., Harpaz N., Itzkowitz S., et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 2007, 133:1099-1105. quiz 1340-1341.
13. Rutter M., Saunders B., Wilkinson K., et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004, 126:451-459.
14. Nieminen U., Jussila A., Nordling S., et al. Inflammation and disease duration have a cumulative effect on the risk of dysplasia and carcinoma in IBD: a case-control observational study based on registry data. Int J Cancer 2014, 134:189-196.
15. Rubin D.T., Huo D., Kinnucan J.A., et al. Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case-control study. Clin Gastroenterol Hepatol 2013, 11:1601-1608.
16. Aleksandrova K., Jenab M., Boeing H., et al. Circulating C-reactive protein concentrations and risks of colon and rectal cancer: a nested case-control study within the European Prospective Investigation into Cancer and Nutrition. Am J Epidemiol 2010, 172:407-418.
17. Chan A.T., Ogino S., Giovannucci E.L., et al. Inflammatory markers are associated with risk of colorectal cancer and chemopreventive response to anti-inflammatory drugs. Gastroenterology 2011, 140:799-808. quiz e11.
18. Erlinger T.P., Platz E.A., Rifai N., et al. C-reactive protein and the risk of incident colorectal cancer. JAMA 2004, 291:585-590.
19. Solem C.A., Loftus E.V., Tremaine W.J., et al. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 2005, 11:707-712.
20. Vermeire S., Van Assche G., Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis 2004, 10:661-665.
21. Boirivant M., Leoni M., Tariciotti D., et al. The clinical significance of serum C reactive protein levels in Crohn's disease: results of a prospective longitudinal study. JClin Gastroenterol 1988, 10:401-405.
22. Henriksen M., Jahnsen J., Lygren I., et al. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease-results from a prospective population-based study. Gut 2008, 57:1518-1523.
23. Lewis J.D. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology 2011, 140:1817-1826.
24. Ananthakrishnan A.N., Cagan A., Gainer V.S., et al. Normalization of plasma 25-hydroxy vitamin D is associated with reduced risk of surgery in Crohn's disease. Inflamm Bowel Dis 2013, 19:1921-1927.
25. Ananthakrishnan A.N., Cai T., Savova G., et al. Improving case definition of Crohn's disease and ulcerative colitis in electronic medical records using natural language processing: a novel informatics approach. Inflamm Bowel Dis 2013, 19:1411-1420.
26. Ford E.S. Body mass index and colon cancer in a national sample of adult US men and women. Am J Epidemiol 1999, 150:390-398.
27. Dregan A., Moller H., Murray-Thomas T., et al. Validity of cancer diagnosis in a primary care database compared with linked cancer registrations in England: population-based cohort study. Cancer Epidemiol 2012, 36:425-429.
28. Molodecky N.A., Myers R.P., Barkema H.W., et al. Validity of administrative data for the diagnosis of primary sclerosing cholangitis: a population-based study. Liver Int 2011, 31:712-720.
29. Grivennikov S.I. Inflammation and colorectal cancer: colitis-associated neoplasia. Semin Immunopathol 2013, 35:229-244.
30. Oussalah A., Chevaux J.B., Fay R., et al. Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy. Am J Gastroenterol 2010, 105:1142-1149.
31. Burstein E., Fearon E.R. Colitis and cancer: a tale of inflammatory cells and their cytokines. JClin Invest 2008, 118:464-467.
32. Tsilidis K.K., Branchini C., Guallar E., et al. C-reactive protein and colorectal cancer risk: a systematic review of prospective studies. Int J Cancer 2008, 123:1133-1140.
33. Popivanova B.K., Kitamura K., Wu Y., et al. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. JClin Invest 2008, 118:560-570.
34. Li Y., de Haar C., Chen M., et al. Disease-related expression of the IL6/STAT3/SOCS3 signalling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis. Gut 2010, 59:227-235.
35. Atreya R., Mudter J., Finotto S., et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis invivo. Nat Med 2000, 6:583-588.
36. Fukata M., Abreu M.T. Role of Toll-like receptors in gastrointestinal malignancies. Oncogene 2008, 27:234-243.
37. Monteleone G., Pallone F., Stolfi C. The dual role of inflammation in colon carcinogenesis. Int J Mol Sci 2012, 13:11071-11084.
38. Santaolalla R., Sussman D.A., Ruiz J.R., et al. TLR4 activates the beta-catenin pathway to cause intestinal neoplasia. PLoS One 2013, 8:e63298.
39. Neurath M.F., Travis S.P. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut 2012, 61:1619-1635.
40. Sandborn W.J. The future of inflammatory bowel disease therapy: where do we go from here?. Dig Dis 2012, 30(Suppl 3):140-144.
41. Ananthakrishnan A.N., Korzenik J.R., Hur C. Can mucosal healing be a cost-effective endpoint for biologic therapy in Crohn's disease? A decision analysis. Inflamm Bowel Dis 2013, 19:37-44.
42. Vermeire S., Van Assche G., Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys?. Gut 2006, 55:426-431.
43. Vermeire S., Van Assche G., Rutgeerts P. The role of C-reactive protein as an inflammatory marker in gastrointestinal diseases. Nat Clin Pract Gastroenterol Hepatol 2005, 2:580-586.